Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06047626
Other study ID # UMCC 2023.015
Secondary ID HUM00230256
Status Recruiting
Phase N/A
First received
Last updated
Start date March 7, 2024
Est. completion date September 2028

Study information

Verified date June 2024
Source University of Michigan Rogel Cancer Center
Contact Sara Snyder
Phone 734-998-7124
Email fammed-szickstudy@med.umich.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study the investigators are proposing to evaluate the efficacy, sustainability, and mechanisms of 3 months of individualized counseling of the FRD delivered by registered dietitians, over 8 sessions by phone/video conferencing on fatigue, quality of life, and associated symptoms in persistently fatigued lymphoma cancer survivors compared to 3 months of individualized counseling of the attention control (matched for time and frequency of interactions with the FRD) the General Health Curriculum (GHC). The investigators will randomize and follow 68 lymphoma cancer survivors; accounting for a ~10% drop out rate to achieve a target of 60 patients that will complete the study. The investigators hypothesize that persistently fatigued lymphoma cancer survivors will experience improvements in fatigue, quality of life, and symptoms commonly associated with fatigue, which are then maintained at 15-months post-enrollment; and decreased CRP and alterations in inflammation-associated DNA methylation consistent with reduced inflammation from following the FRD as compared to the GHC.


Recruitment information / eligibility

Status Recruiting
Enrollment 68
Est. completion date September 2028
Est. primary completion date September 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Women and men aged 18 years and older - Diagnosis of lymphoma (Hodgkin and non-Hodgkin) - Have an average persistent fatigue defined as = 4 on the Brief Fatigue Inventory - Fatigue must have started at or after the diagnosis of Lymphoma - Fruit and vegetable intake =5.5 servings/day - Have, or be willing to create, an email address to receive study questionnaires electronically. Exclusion Criteria: - Medically unstable - BMI<18.5 kg/m2 - Have a current untreated diagnosis of mood disorder, e.g., bipolar or major depressive disorder - Have a current untreated diagnosis of anemia - Have a current untreated diagnosis of hypothyroidism - Have an initiation, a cessation or change of treatment of any chronic medications, dietary supplements, behavioral therapy, physical therapy etc., or any planned change of medications, supplements, or therapies during the study - Have a current diagnoses of cachexia - Planning on becoming pregnant, currently pregnant or lactating

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Fatigue Reduction Diet
Sessions will be ~15 minutes for 8 sessions. The FRD maintains participants on a diet with their typical caloric intake as assessed at baseline, and replaces some of their calories with the following foods on a daily basis: at least 50% of servings grains to be whole grains (these would replace non-whole grain foods); 5 servings of vegetables (1 leafy green, 1 tomato, and 1 yellow/orange); 2 servings of fruit (1 high in vitamin C), both fruit and vegetables would replace some of the carbohydrates from non-fruit and vegetable sources; 1 serving of fatty fish and or 1 serving of nuts and/or seeds (2 servings of nuts and/or seeds for vegetarians), both the fish, the nuts, and seeds will replace existing sources of fats and proteins in the diet.
General Health Curriculum
These sessions will be matched counseling method, time spent (~15 minutes per session), for 8 sessions. Registered Dietitians will discuss general health topics with the participant, excluding topics of diet and food.

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan

Sponsors (2)

Lead Sponsor Collaborator
University of Michigan Rogel Cancer Center American Institute for Cancer Research

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Brief Fatigue Inventory To examine the effect of 3 months of FRD compared to an attention control GHC on persistent fatigue, measured with the Brief Fatigue Inventory. The instrument consists of 9 items, each measuring fatigue on a 0-10 scale, and is calculated from the mean of completed items 3 months after enrollment
Secondary Examining the effect of 3 months of FRD compared to an attention control GHC on Quality of life Quality of life, using the Functional Assessment of Chronic Illness Therapy Measurement System, specifically the lymphoma cancer specific instrument. The total score will be our primary outcome. The FACT-G has demonstrated reliability, validity, and responsiveness to change over time. 3 months after enrollment
Secondary The effect of 3 months of FRD compared to an attention control GHC on persistent sleep disturbance Using the PROMIS SF v1.0- Sleep Disturb 8b survey 3 months after enrollment
Secondary The effect of 3 months of FRD compared to an attention control GHC on persistent pain Using the PROMIS SF v1.1- Pain Interference 8a survey 3 months after enrollment
Secondary The effect of 3 months of FRD compared to an attention control GHC on persistent mood Using the PROMIS SF v1.0 Anxiety 7a and Depression 8b surveys 3 months after enrollment
Secondary The effect of 3 months of FRD compared to an attention control GHC on persistent sexual function Using the PROMIS Sexual Function Profile v1.0 Mal and Female surveys 3 months after enrollment
Secondary Examining the effect of 3 months of FRD compared to an attention control GHC on adherence to program Adherence measured with a food frequency questionnaire (FFQ) and food checklists. 3 months after enrollment
Secondary Examining the acceptability of the FRD program- FRD initiation Acceptability via semi-structured interviews (only in the FRD arm), specifically barriers and facilitators to FRD initiation 3 months after enrollment
Secondary Number of subjects who withdraw from study (acceptability) Acceptability via withdrawals over the 3-month intervention phase 3 months after enrollment
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1